Telix Pharmaceuticals Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 1,184

Employees

  • Stock Symbol
  • TLX

Stock Symbol

  • Investments
  • 17

  • Share Price
  • $8.60
  • (As of Friday Closing)

Telix Pharmaceuticals General Information

Description

Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 55 Flemington Road
  • Level 4
  • North Melbourne, Victoria 3051
  • Australia
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
ASX
Vertical(s)
Corporate Office
  • 55 Flemington Road
  • Level 4
  • North Melbourne, Victoria 3051
  • Australia

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Telix Pharmaceuticals Stock Performance

As of 20-Nov-2026, Telix Pharmaceuticals’s stock price is $8.60. Its current market cap is $2.92B with 340M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.60 $8.87 $5.84 - $13.00 $2.92B 340M 2.09M $0.10

Telix Pharmaceuticals Financials Summary

As of 30-Jun-2026, Telix Pharmaceuticals has a trailing 12-month revenue of $891M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 4,199,873 2,725,850 5,062,230 2,146,340
Revenue 890,785 803,794 516,551 332,978
EBITDA 68,097 29,324 54,885 10,866
Net Income 33,497 (7,125) 33,685 4,208
Total Assets 1,361,851 1,163,986 940,379 277,258
Total Debt 579,861 467,106 360,162 12,264
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Telix Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Telix Pharmaceuticals‘s full profile, request access.

Request a free trial

Telix Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes
Pharmaceuticals
North Melbourne, Australia
1,184 As of 2025

Columbus, OH
 

Eveleigh, Australia
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Telix Pharmaceuticals Competitors (6)

One of Telix Pharmaceuticals’s 6 competitors is Sermonix Pharmaceuticals, a Venture Capital-Backed company based in Columbus, OH.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sermonix Pharmaceuticals Venture Capital-Backed Columbus, OH
Clarity Pharmaceuticals Formerly VC-backed Eveleigh, Australia
Gilead Formerly VC-backed Foster City, CA
AdvanCell Venture Capital-Backed Boston, MA
Cantex Pharmaceuticals Formerly VC-backed Weston, FL
To view Telix Pharmaceuticals’s complete competitors history, request access »

Telix Pharmaceuticals Patents

Telix Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026059931-A2 Dll3 antigen binding constructs Pending 11-Sep-2024
WO-2026059931-A3 Dll3 antigen binding constructs Pending 11-Sep-2024
AU-2025310414-A1 Antibodies and methods of making and using same Pending 26-Jul-2024
WO-2026024987-A1 Antibodies and methods of making and using same Pending 26-Jul-2024
AU-2024346987-A1 Antigen binding constructs Pending 19-Sep-2023 C07K16/00
To view Telix Pharmaceuticals’s complete patent history, request access »

Telix Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Telix Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Telix Pharmaceuticals‘s full profile, request access.

Request a free trial

Telix Pharmaceuticals Investments & Acquisitions (17)

Telix Pharmaceuticals’s most recent deal was a Merger/Acquisition with ITM Isotope Technologies Munich for . The deal was made on 21-Sep-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ITM Isotope Technologies Munich 21-Sep-2026 Merger/Acquisition Biotechnology
Telix Innovations Brazil 17-Mar-2025 Joint Venture Pharmaceuticals
SCV (Fibroblast Activation Protein Located in Germany) 12-Mar-2025 Corporate Asset Purchase Buildings and Property
ImaginAb (Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform) 30-Jan-2025 Corporate Asset Purchase Buildings and Property
RLS Radiopharmacies 28-Jan-2025 Merger/Acquisition Specialty Retail
You’re viewing 5 of 17 investments and acquisitions. Get the full list »

Telix Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

29.83 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Telix Pharmaceuticals’s complete esg history, request access »

Telix Pharmaceuticals Affiliates

Subsidiaries (7)

Name Industry Location Year Founded
RLS Radiopharmacies Lake Mary, FL 2019
Dedicaid Vienna, Austria 2018
Optimal Tracers Sacramento, CA 2013
ARTMS Burnaby, Canada 2013
Lightpoint Medical Amersham, United Kingdom 2012
You’re viewing 5 of 7 affiliates. Get the full list.  »

Telix Pharmaceuticals FAQs

  • When was Telix Pharmaceuticals founded?

    Telix Pharmaceuticals was founded in 2015.

  • Where is Telix Pharmaceuticals headquartered?

    Telix Pharmaceuticals is headquartered in North Melbourne, Australia.

  • What is the size of Telix Pharmaceuticals?

    Telix Pharmaceuticals has 1,184 total employees.

  • What industry is Telix Pharmaceuticals in?

    Telix Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Telix Pharmaceuticals a private or public company?

    Telix Pharmaceuticals is a Public company.

  • What is Telix Pharmaceuticals’s stock symbol?

    The ticker symbol for Telix Pharmaceuticals is TLX.

  • What is the current stock price of Telix Pharmaceuticals?

    As of 20-Nov-2026 the stock price of Telix Pharmaceuticals is $8.60.

  • What is the current market cap of Telix Pharmaceuticals?

    The current market capitalization of Telix Pharmaceuticals is $2.92B.

  • What is Telix Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Telix Pharmaceuticals is $891M.

  • Who are Telix Pharmaceuticals’s competitors?

    Sermonix Pharmaceuticals, Clarity Pharmaceuticals, Gilead, AdvanCell, and Cantex Pharmaceuticals are some of the 6 competitors of Telix Pharmaceuticals.

  • What is Telix Pharmaceuticals’s annual earnings per share (EPS)?

    Telix Pharmaceuticals’s EPS for 12 months was $0.10.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process